All Studies = Prognostic
Pre = Predictive
Mon = Monitoring
ET = Endocrine Therapy
CDK = CDK476 inhibitors
Published Studies for the DiviTum® TKa Test
The DiviTum® TKa test has been studied widely in HR+ metastatic breast cancer, as well as in other solid tumor types. The evidence demonstrates that measuring thymidine kinase activity (TKa) levels with the DiviTum TKa test provides important clinical information for the management of the disease.
24+ publications support the application of DiviTum® TKa to prognose, predict, and monitor response to anti-cancer agents such as endocrine therapies and CDK4/6 inhibitors.
Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor 2–negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial. [Journal of Clinical Oncology, June 2022]